National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding
Two sections of the guideline, HPV oncogenic types not 16/18 and Self-collected vaginal samples have been reviewed and updated. Updated guidance came into effect on 1 February 2021.
For further information, see: Review of National Cervical Screening Program data and partial update.
To be notified about the launch of updated guideline content, contact guidelines(at)cancer.org.au.
Clinical management guidelines for the prevention of cervical cancer[edit source]
8. Management of discordant colposcopic impression, histopathology and referral LBC prediction[edit source]
15. Screening in women who have experienced early sexual activity or have been victims of sexual abuse[edit source]
18. Signs and symptoms of cervical cancer[edit source]
- A. Modelled evaluation of the predicted benefits, harms and cost-effectiveness of the renewed National Cervical Screening Program (NCSP) in conjunction with these guideline recommendations
- B. Guidelines development process
- C. Clinical question list
- D. Technical report
- E. & F. Working party members and contributors
- G. Conflict of interest register
- H. Safety monitoring of the Renewed cervical screening program
- I. Glossary (terms and abbreviations)
Please see the Australian Department of Health Cancer Screening website for information about the National Cervical Screening Program (NCSP) and policies on transitioning women to the renewed NCSP.